TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34695232

Group type: EXPERIMENTAL
Intervention: 200 μg vaginal misoprostol
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 800 μg vaginal misoprostol
Number of subjects: 76
Study: 33559272

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with oral polyethylene glycol (PEG) solution
Number of subjects: 144

Group type: COMPARATOR
Intervention: Liquid diet on the preoperative day
Number of subjects: 144

Group type: COMPARATOR
Intervention: Minimal residue diet for 3 days
Number of subjects: 144
Study: 35165727

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg once daily for 6 days (3 days orally and 3 days intravenously)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (LPS 2 ng/kg body weight without tedizolid)
Number of subjects: 14
Study: 33472259

Group type: EXPERIMENTAL
Intervention: Spacer Block Tool (SBT) used for joint line (JL) reconstruction in Group 2
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional methods for joint line (JL) reconstruction in Group 1
Number of subjects: 45
Study: 34022796

Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg/day)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg/day)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Vonoprazan
Number of subjects: 168

Group type: COMPARATOR
Intervention: Lansoprazole
Number of subjects: 168
Study: 32422956

Group type: EXPERIMENTAL
Intervention: 52 mL/day of EVOO
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: DieTBra
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: DieTBra + 52 mL/day of EVOO
Number of subjects: 149
Study: 33530693

Group type: EXPERIMENTAL
Intervention: Educational Video
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard Verbal Consent
Number of subjects: 77
Study: 32865608

Group type: EXPERIMENTAL
Intervention: Additional multiple-choice questions accompanying lectures
Number of subjects: 675

Group type: COMPARATOR
Intervention: Supplementary online material only
Number of subjects: 675
Study: 34455213

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 international units)
Number of subjects: 34
Study: 32543439

Group type: EXPERIMENTAL
Intervention: Multilayer Perceptron model for SMS reply triage
Number of subjects: 3118

Group type: EXPERIMENTAL
Intervention: Ensemble model for SMS reply triage
Number of subjects: 3118

Group type: EXPERIMENTAL
Intervention: OneVsRest model for 12-category classification
Number of subjects: 3118
Study: 32976085

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 46
Study: 35908159

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CIV) of enoxaparin 40 mg per day for 72 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subcutaneous bolus (SCB) injection of enoxaparin 40 mg per day for 72 hours
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both CIV and SCB administration of enoxaparin after 72 hours
Number of subjects: 40
Study: 34783727

Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (amplitude of 3mm, frequency of 20Hz, 12 sessions, 5 bouts of 120 seconds with 60s rest intervals, 6 days/week for 2 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine physiotherapy (12 sessions)
Number of subjects: 64
Study: 32868548

Group type: EXPERIMENTAL
Intervention: Prospective pharmacist verification process on all ED discharge prescriptions
Number of subjects: 750

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 750
Study: 36067740

Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning (IC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: IC Sham
Number of subjects: 43
Study: 32613244

Group type: EXPERIMENTAL
Intervention: Vacuum‐formed retainer (VFR) in the mandible (n = 52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Bonded cuspid‐to‐cuspid retainers (CTC) (n = 52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups (VFR and CTC)
Number of subjects: 104
Study: 34968373

Group type: EXPERIMENTAL
Intervention: Full vaccination with Pfizer-BioNTech vaccine (2 doses, ≥14 days after the second dose)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Partially vaccinated (1 dose or 2 doses <14 days)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 243
Study: 33339768

Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Number of subjects: 144

Group type: COMPARATOR
Intervention: IVA
Number of subjects: 144
Study: 33332232

Group type: EXPERIMENTAL
Intervention: Full body photobiomodulation therapy (PBMT) with a dose of 6.9 J/cm2, irradiance of 46.17 mW/cm2, 5 min irradiation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 13
Study: 35226113

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) following standard epineural nerve repair
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard epineural nerve repair without HBOT
Number of subjects: 74
Study: 35758652

Group type: EXPERIMENTAL
Intervention: Suvratoxumab (monoclonal antibody targeting S. aureus alpha-toxin)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study: 32165554

Group type: EXPERIMENTAL
Intervention: Circumferential (C) spread
Number of subjects: 124
Study: 33150590

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg for 3 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 33980220

Group type: EXPERIMENTAL
Intervention: Use of webcams in NICUs
Number of subjects: 730
Study: 33547713

Group type: EXPERIMENTAL
Intervention: Automatic positive airway pressure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 50
Study: 36375643

Group type: EXPERIMENTAL
Intervention: Liraglutide therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (RYGB or SG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (RYGB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bariatric surgery vs. liraglutide therapy
Number of subjects: 0
Study: 33103229

Group type: EXPERIMENTAL
Intervention: Pulse methylprednisolone therapy (30 mg/kg/d for five days followed by oral steroids 1 mg/kg tapered over 5-6 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intramuscular adrenocorticotropic hormone (ACTH) therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: ACTH therapy
Number of subjects: 44
Study: 32423392

Group type: COMPARATOR
Intervention: Standard formula (SF) - cow's milk based infant formula with DHA (17 mg/100 kcal) and ARA (25 mg/100 kcal); 1.9 g protein/100 kcal; 1.2 mg Fe/100 kcal
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Experimental formula (EF) - similar infant formula with added source of bovine MFGM (whey protein-lipid concentrate)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Experimental formula (EF)
Number of subjects: 540
Study: 36259713

Group type: EXPERIMENTAL
Intervention: RDN+AF ablation
Number of subjects: 61

Group type: COMPARATOR
Intervention: AF-only ablation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 34187832

Group type: EXPERIMENTAL
Intervention: Seroprevalence of anti-SARS-CoV-2 antibodies
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Seroconversion during follow-up
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Neutralising antibodies
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: RT-qPCR results
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: COVID-19-compatible symptoms
Number of subjects: 850
Study: 32042439

Group type: EXPERIMENTAL
Intervention: GENIE intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 22
Study: 34850808

Group type: EXPERIMENTAL
Intervention: Tissue adhesive zipper for 3 months after surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no tissue adhesive zipper)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 33619370

Group type: EXPERIMENTAL
Intervention: Topical ShA9
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 54
Study: 33799084

Group type: EXPERIMENTAL
Intervention: Group readiness assurance test
Number of subjects: 194
Study: 32057470

Group type: EXPERIMENTAL
Intervention: Digitised condylar retractor
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional surgical instruments
Number of subjects: 48
Study: 35039272

Group type: EXPERIMENTAL
Intervention: Cooling blood detoxification decoction plus traditional Chinese medicine (TCM) care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine treatment plus routine nursing
Number of subjects: 120
Study: 34585780

Group type: EXPERIMENTAL
Intervention: Single 5 mg dose of zoledronate
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 5-yearly doses of 2.5 mg zoledronate
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Redosing with 1 mg zoledronate
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Redosing with 2.5 mg zoledronate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 33940213

Group type: COMPARATOR
Intervention: Maintaining low-dose ICS/LABA (G1)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Discontinuing LABA (G2)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Reducing ICS/LABA to once daily (G3)
Number of subjects: 225
Study: 32089025

Group type: EXPERIMENTAL
Intervention: Counseling based on Gamble's approach (3 sessions before delivery and 1 session postpartum)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine prenatal care (Control)
Number of subjects: 60
Study: 33407787

Group type: EXPERIMENTAL
Intervention: Inhibitory repetitive transcranial magnetic stimulation (r-TMS) applied over the left intact parietal cortex followed by visual scanning treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation (SHAM control) followed by visual scanning treatment
Number of subjects: 0
Study: 32891284

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (no extra virgin olive oil)
Number of subjects: 129
Study: 35769675

Group type: EXPERIMENTAL
Intervention: Grandioseal, Voco, Germany
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Smartseal & Loc, Detax Gmbh & Co, Germany
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fuji triage capsule, GC, Belgium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 34431611

Group type: EXPERIMENTAL
Intervention: Food addiction framing
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control passage about memory
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Eating addiction framing
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Calorie balance explanations for obesity
Number of subjects: 447
Study: 35604035

Group type: COMPARATOR
Intervention: Adhesive applied according to the manufacturers' recommendations (control group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Doubling the adhesive application time
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Applying double adhesive layers
Number of subjects: 39
Study: 33534199

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 23
Study: 34904623

Group type: EXPERIMENTAL
Intervention: HPV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional treatments
Number of subjects: 0
Study: 32070681

Group type: EXPERIMENTAL
Intervention: ART-Def (initiating ART following immunological or clinical deterioration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART-Immed/40w (initiating ART immediately upon enrolment, interrupted at 40 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ART-Immed/96w (initiating ART immediately upon enrolment, interrupted at 96 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose of PCV7 or HibCV at 15 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-unexposed children
Number of subjects: 0

Group type: COMPARATOR
Intervention: HEU (HIV-exposed uninfected) children
Number of subjects: 0
Study: 34042412

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD) treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo SWD treatment (Control)
Number of subjects: 42
Study: 33596959

Group type: EXPERIMENTAL
Intervention: Avoiding routine drain placement (experimental arm)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Prophylactic drain placement (control arm)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Overall morbidity and mortality (secondary endpoint)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Comprehensive Complications Index (secondary endpoint)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Incidence and time for diagnosis of anastomotic and duodenal leaks (secondary endpoint)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Length of hospital stay (secondary endpoint)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Readmission rate (secondary endpoint)
Number of subjects: 404
Study: 32507842

Group type: EXPERIMENTAL
Intervention: Pharmacologic intervention for hyperlipidaemia with LDL-C level of 3.36 mmol/l (130 mg/dl) as the threshold.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pharmacologic intervention for hyperglycaemia with fasting plasma glucose of ≥5.3 mmol/l (95 mg/dl) and 2-hour postprandial glucose level of 7.8 mmol/l (140 mg/dl) as the threshold.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Initiating treatment for hypertension at blood pressure of ≥130/≤89 mmHg or ≤139/≥85 mmHg.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pharmacologic intervention for hypertensive patients (BP ≥160/≥100 mmHg) with total cholesterol of 6.5 mmol/l (251.35 mg/dl) or higher.
Number of subjects: 16
Study: 36171728

Group type: EXPERIMENTAL
Intervention: Instrument-Assisted Soft Tissue Mobilization (IASTM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Muscle Energy Technique (MET)
Number of subjects: 26
Study: 33993064

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TTh) for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle intervention alone
Number of subjects: 0
Study: 33844568

Group type: EXPERIMENTAL
Intervention: ACH + CM
Number of subjects: 21

Group type: COMPARATOR
Intervention: ACH alone
Number of subjects: 21
Study: 32107288

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (ET)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Successful recanalization (defined as modified Thrombolysis in Cerebral Infarction Score, mTICI 2b/3)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Age <70 years
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: NIHSS <12
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Higher age, pre‐stroke MRS score >1, failed recanalization
Number of subjects: 152
Study: 33739957

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 70

Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 70
Study: 32248629

Group type: EXPERIMENTAL
Intervention: FM 2016 criteria
Number of subjects: 2531

Group type: COMPARATOR
Intervention: AAPT criteria
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Physician diagnosed fibromyalgia
Number of subjects: 2531
Study: 35589454

Group type: EXPERIMENTAL
Intervention: Personal justice-only writing intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Justice writing conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive injustice writing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral writing condition (control)
Number of subjects: 0
Study: 33390060

Group type: EXPERIMENTAL
Intervention: Demographic and Health Survey questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Questionnaire incorporating an event history calendar, recall cues, and increased probing strategies
Number of subjects: 0
Study: 32551725

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nonimprovers
Number of subjects: 108
Study: 36454721

Group type: EXPERIMENTAL
Intervention: Use of fan when air cleaner was on low setting
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Use of air cleaner on high setting (compared to low) when fan was off
Number of subjects: 2
Study: 33839076

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.075 to 0.1 ug/kg/min for 24 h, once weekly for 6 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 35760340

Group type: EXPERIMENTAL
Intervention: Loaner Digital Device (Bluetooth enabled iPad with data plan coverage)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Loaner Digital Device + Coaching Support (loaner device plus up to six, 15–20 min motivational interviewing‐based coaching calls)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control Condition (no additional study intervention)
Number of subjects: 90
Study: 33821578

Group type: EXPERIMENTAL
Intervention: Long-term PDE5Is
Number of subjects: 109

Group type: COMPARATOR
Intervention: Not on PDE5Is
Number of subjects: 109
Study: 34585254

Group type: EXPERIMENTAL
Intervention: Vascular surgery
Number of subjects: 125

Group type: COMPARATOR
Intervention: Non-vascular surgery
Number of subjects: 125
Study: 33938917

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 5179

Group type: COMPARATOR
Intervention: Invasive management
Number of subjects: 5179
Study: 36113908

Group type: EXPERIMENTAL
Intervention: Exposure-based treatment for perfectionism (ETP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 71
Study: 34543257

Group type: EXPERIMENTAL
Intervention: Cap-assisted technique
Number of subjects: 342

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 342
Study: 35549944

Group type: EXPERIMENTAL
Intervention: SEMS group (self-expanding metallic stents)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no SEMS)
Number of subjects: 87
Study: 34061467

Group type: EXPERIMENTAL
Intervention: New CLL score including CD43 and CD180
Number of subjects: 237
Study: 35241051

Group type: EXPERIMENTAL
Intervention: Amine fluoride toothpaste (1400 ppmF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate toothpaste (1450 ppmF)
Number of subjects: 120
Study: 33407337

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Hyaluronic acid after arthroscopic lateral release.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Arthroscopic lateral release only (Control Group B).
Number of subjects: 90
Study: 35666545

Group type: EXPERIMENTAL
Intervention: Single-dose topical dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34685778

Group type: EXPERIMENTAL
Intervention: Spironolactone treatment (verum)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 386
Study: 35002984

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no metformin therapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (GA improved subgroup)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (GA unimproved subgroup)
Number of subjects: 100
Study: 32151500

Group type: EXPERIMENTAL
Intervention: Neuromobilization exercise program (NEP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 30
Study: 32342892

Group type: EXPERIMENTAL
Intervention: DSS with 100% reliability
Number of subjects: 36

Group type: COMPARATOR
Intervention: DSS with 90% reliability
Number of subjects: 36

Group type: COMPARATOR
Intervention: DSS with 80% reliability
Number of subjects: 36

Group type: COMPARATOR
Intervention: DSS with undisclosed reliability
Number of subjects: 36
Study: 33078322

Group type: EXPERIMENTAL
Intervention: Menghini-type needle (needle M)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional needle (needle S)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 97
Study: 33272368

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 35837707

Group type: EXPERIMENTAL
Intervention: Denosumab (short-course, varying from 3 to 6 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisphosphonate-loaded bone cement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous microwave ablation and bisphosphonate-loaded polymethylmethacrylate cementoplasty
Number of subjects: 0
Study: 33492894

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention Group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care Group
Number of subjects: 0
Study: 35910056

Group type: EXPERIMENTAL
Intervention: 500 IU hCG
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 1000 IU hCG
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (no hCG)
Number of subjects: 174
Study: 32524511

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medicines optimisation clinic
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 35553286

Group type: EXPERIMENTAL
Intervention: Healer-delivered counseling and point-of-care HIV tests
Number of subjects: 173

Group type: COMPARATOR
Intervention: Referral for clinic-based testing
Number of subjects: 173
Study: 32876737

Group type: EXPERIMENTAL
Intervention: 3D viewing mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2D viewing mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D → 2D
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3D → 3D
Number of subjects: 0
Study: 32599336

Group type: EXPERIMENTAL
Intervention: Late preterm children
Number of subjects: 652

Group type: COMPARATOR
Intervention: Term children
Number of subjects: 652
Study: 35674762

Group type: EXPERIMENTAL
Intervention: Trifarotene 0.005% cream
Number of subjects: 0
Study: 34254673

Group type: EXPERIMENTAL
Intervention: Cenobamate (median dose 200 mg, range 50–400 mg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 149